Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Mitochondrial DNA Haplogroup JT is Related to Impaired Glycaemic Control and Renal Function in Type 2 Diabetic Patients

  • Diaz-Morales, N.
  • Lopez-Domenech, S.
  • Iannantuoni, F.
  • Lopez-Gallardo, E.
  • Sola, E.
  • Morillas, C.
  • Rocha, M.
  • Ruiz-Pesini, E.
  • Victor, V.M.
The association between mitochondrial DNA (mtDNA) haplogroup and risk of type 2 diabetes (T2D) is undetermined and controversial. This study aims to evaluate the impact of the main mtDNA haplogroups on glycaemic control and renal function in a Spanish population of 303 T2D patients and 153 healthy controls. Anthropometrical and metabolic parameters were assessed and mtDNA haplogroup was determined in each individual. Distribution of the different haplogroups was similar in diabetic and healthy populations and, as expected, T2D patients showed poorer glycaemic control and renal function than controls. T2D patients belonging to the JT haplogroup (polymorphism m.4216T>C) displayed statistically significant higher levels of fasting glucose and HbA(1c) than those of the other haplogroups, suggesting a poorer glycaemic control. Furthermore, diabetic patients with the JT haplogroup showed a worse kidney function than those with other haplogroups, evident by higher levels of serum creatinine, lower estimated glomerular filtration rate (eGFR), and slightly higher (although not statistically significant) urinary albumin-to-creatinine ratio. Our results suggest that JT haplogroup (in particular, change at position 4216 of the mtDNA) is associated with poorer glycaemic control in T2D, which can trigger the development of diabetic nephropathy.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Las enfermedades raras en las patologías neurometabólicas

  • Montoya, J.
  • Arenas, J.
  • Ruiz-Pesini, E.
  • Martin-Casanueva, M.A.
Las miopatías metabólicas son un grupo de trastornos genéticos que disminuyen la capacidad del músculo esquelético para utilizar sustratos energéticos y sintetizar ATP. Estas alteraciones pueden clasificarse en tres tipos fundamentalmente: i) trastornos del metabolismo de los carbohidratos (del glucógeno y de la glucosa), ii) defectos del metabolismo lipídico, y iii) alteraciones de la fosforilación oxidativa –OXPHOS-. Las dos primeras se deben a deficiencias enzimáticas de las rutas metabólicas de degradación y síntesis de glúcidos y lípidos y muestran diversas manifestaciones clínicas, pero una buena parte de ellas cursan con intolerancia al ejercicio. Aunque un buen número de pacientes con estos trastornos musculares presentan síntomas en la infancia, el diagnóstico normalmente se retrasa hasta la segunda y tercera década de la vida. Por tanto, reconocer las características clínicas de estas deficiencias conduce a un diagnóstico precoz y a un mejor tratamiento. Las enfermedades mitocondriales son un grupo de trastornos originados por una deficiencia en la síntesis de ATP a través del sistema de fosforilación oxidativa. Este sistema está formado por proteínas codificadas en los dos genomas de la célula (nuclear y mitocondrial) y, por tanto, pueden presentar un modelo de herencia mendeliano o materno. En esta revisión se describirán las características especiales del sistema genético mitocondrial y las principales mutaciones que causan enfermedades en humanos. Metabolic myopathies are genetic disorders that decrease the capacity of skeletal muscle to use energy substrates and ATP. These disturbances can be classified into three categories: i) disorders of carbohydrate metabolism (glycogen and glucose), ii) defects in lipid metabolism, and iii) dysfunctions of oxidative phosphorylation -OXPHOS-. The first two are caused by enzyme deficiencies involved in the metabolic pathways of degradation and synthesis of carbohydrates and lipids, and although they show distinct clinical manifestations, exercise intolerance is a predominant symptom present in most of them. Although a good number of patients with these muscle disorders display symptoms in childhood, the diagnosis is often delayed until the second and third decades of life. Therefore, recognizing the clinical features of these deficiencies can lead to an earlier diagnosis and better treatment. Mitochondrial diseases are a group of disorders caused by an alteration of the oxidative phosphorylation system, that leads to a deficient synthesis of ATP. This system is composed of proteins codified in the two genetic systems of the cell, the nuclear and mitochondrial genomes, and, therefore, the mode of inheritance could be either Mendelian or maternal. This review will describe the special characteristics of the mitochondrial genetic system and the main mutations in mtDNA that cause human diseases.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Plasma coenzyme Q10 status is impaired in selected genetic conditions

  • Montero, R.
  • Yubero, D.
  • Salgado, M.C.
  • González, M.J.
  • Campistol, J.
  • O''Callaghan, M.D.M.
  • Pineda, M.
  • Delgadillo, V.
  • Maynou, J.
  • Fernandez, G.
  • Montoya, J.
  • Ruiz-Pesini, E.
  • Meavilla, S.
  • Neergheen, V.
  • García-Cazorla, A.
  • Navas, P.
  • Hargreaves, I.
  • Artuch, R.
Identifying diseases displaying chronic low plasma Coenzyme Q10 (CoQ) values may be important to prevent possible cardiovascular dysfunction. The aim of this study was to retrospectively evaluate plasma CoQ concentrations in a large cohort of pediatric and young adult patients. We evaluated plasma CoQ values in 597 individuals (age range 1 month to 43 years, average 11 years), studied during the period 2005-2016. Patients were classified into 6 different groups: control group of healthy participants, phenylketonuric patients (PKU), patients with mucopolysaccharidoses (MPS), patients with other inborn errors of metabolism (IEM), patients with neurogenetic diseases, and individuals with neurological diseases with no genetic diagnosis. Plasma total CoQ was measured by reverse-phase high-performance liquid chromatography with electrochemical detection and ultraviolet detection at 275¿nm. ANOVA with Bonferroni correction showed that plasma CoQ values were significantly lower in the PKU and MPS groups than in controls and neurological patients. The IEM group showed intermediate values that were not significantly different from those of the controls. In PKU patients, the Chi-Square test showed a significant association between having low plasma CoQ values and being classic PKU patients. The percentage of neurogenetic and other neurological patients with low CoQ values was low (below 8%). In conclusión, plasma CoQ monitoring in selected groups of patients with different IEM (especially in PKU and MPS patients, but also in IEM under protein-restricted diets) seems advisable to prevent the possibility of a chronic blood CoQ suboptimal status in such groups of patients.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Food derived respiratory complex I inhibitors modify the effect of Leber hereditary optic neuropathy mutations

  • López-Gallardo, E.
  • Emperador, S.
  • Hernández-Ainsa, C.
  • Montoya, J.
  • Bayona-Bafaluy, M.P.
  • Ruiz-Pesini, E.
Mitochondrial DNA mutations in genes encoding respiratory complex I polypeptides can cause Leber hereditary optic neuropathy. Toxics affecting oxidative phosphorylation system can also cause mitochondrial optic neuropathy. Some complex I inhibitors found in edible plants might differentially interact with these pathologic mutations and modify their penetrance. To analyze this interaction, we have compared the effect of rotenone, capsaicin and rolliniastatin-1 on cybrids harboring the most frequent Leber hereditary optic neuropathy mutations and found that m.3460G > A mutation increases rotenone resistance but capsaicin and rolliniastatin-1 susceptibility. Thus, to explain the pathogenicity of mitochondrial diseases due to mitochondrial DNA mutations, their potential interactions with environment factors will have to be considered.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

NAD(P)HX dehydratase (NAXD) deficiency: a novel neurodegenerative disorder exacerbated by febrile illnesses

  • Van Bergen, N.J.
  • Guo, Y.
  • Rankin, J.
  • Paczia, N.
  • Becker-Kettern, J.
  • Kremer, L.S.
  • Pyle, A.
  • Conrotte, J.F.
  • Ellaway, C.
  • Procopis, P.
  • Prelog, K.
  • Homfray, T.
  • Baptista, J.
  • Baple, E.
  • Wakeling, M.
  • Massey, S.
  • Kay, D.P.
  • Shukla, A.
  • Girisha, K.M.
  • Lewis, L.E.S.
  • Santra, S.
  • Power, R.
  • Daubeney, P.
  • Montoya, J.
  • Ruiz-Pesini, E.
  • Kovacs-Nagy, R.
  • Pritsch, M.
  • Ahting, U.
  • Thorburn, D.R.
  • Prokisch, H.
  • Taylor, R.W.
  • Christodoulou, J.
  • Linster, C.L.
  • Ellard, S.
  • Hakonarson, H.
Physical stress, including high temperatures, may damage the central metabolic nicotinamide nucleotide cofactors [NAD(P)H], generating toxic derivatives [NAD(P)HX]. The highly conserved enzyme NAD(P)HX dehydratase (NAXD) is essential for intracellular repair of NAD(P)HX. Here we present a series of infants and children who suffered episodes of febrile illness-induced neurodegeneration or cardiac failure and early death. Whole-exome or whole-genome sequencing identified recessive NAXD variants in each case. Variants were predicted to be potentially deleterious through in silico analysis. Reverse-transcription PCR confirmed altered splicing in one case. Subject fibroblasts showed highly elevated concentrations of the damaged cofactors S-NADHX, R-NADHX and cyclic NADHX. NADHX accumulation was abrogated by lentiviral transduction of subject cells with wild-type NAXD. Subject fibroblasts and muscle biopsies showed impaired mitochondrial function, higher sensitivity to metabolic stress in media containing galactose and azide, but not glucose, and decreased mitochondrial reactive oxygen species production. Recombinant NAXD protein harbouring two missense variants leading to the amino acid changes p.(Gly63Ser) and p.(Arg608Cys) were thermolabile and showed a decrease in Vmax and increase in KM for the ATP-dependent NADHX dehydratase activity. This is the first study to identify pathogenic variants in NAXD and to link deficient NADHX repair with mitochondrial dysfunction. The results show that NAXD deficiency can be classified as a metabolite repair disorder in which accumulation of damaged metabolites likely triggers devastating effects in tissues such as the brain and the heart, eventually leading to early childhood death.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Molecular characterization of new FBXL4 mutations in patients with mtDNA depletion syndrome

  • Emperador, Sonia
  • Garrido-Pérez, Nuria
  • Amezcua-Gil, Javier
  • Gaudó, Paula
  • Andrés-Sanz, Julio Alberto
  • Yubero, Delia
  • Fernández-Marmiesse, Ana
  • O'Callaghan, Maria M
  • Ortigoza-Escobar, Juan D.
  • Iriondo, Marti
  • Ruiz-Pesini, Eduardo
  • García-Cazorla, Angels
  • Gil-Campos, Mercedes
  • Artuch, Rafael
  • Montoya, Julio
  • Bayona-Bafaluy, María Pilar
Encephalomyopathic mitochondrial DNA (mtDNA) depletion syndrome 13 (MTDPS13) is a rare genetic disorder caused by defects in F-box leucine-rich repeat protein 4 (FBXL4). Although FBXL4 is essential for the bioenergetic homeostasis of the cell, the precise role of the protein remains unknown. In this study, we report two cases of unrelated patients presenting in the neonatal period with hyperlactacidemia and generalized hypotonia. Severe mtDNA depletion was detected in muscle biopsy in both patients. Genetic analysis showed one patient as having in compound heterozygosis a splice site variant c.858+5G>C and a missense variant c.1510T>C (p.Cys504Arg) in FBXL4. The second patient harbored a frameshift novel variant c.851delC (p.Pro284LeufsTer7) in homozygosis. To validate the pathogenicity of these variants, molecular and biochemical analyses were performed using skin-derived fibroblasts. We observed that the mtDNA depletion was less severe in fibroblasts than in muscle. Interestingly, the cells harboring a nonsense variant in homozygosis showed normal mtDNA copy number. Both patient fibroblasts, however, demonstrated reduced mitochondrial transcript quantity leading to diminished steady state levels of respiratory complex subunits, decreased respiratory complex IV (CIV) activity, and finally, low mitochondrial ATP levels. Both patients also revealed citrate synthase deficiency. Genetic complementation assays established that the deficient phenotype was rescued by the canonical version of FBXL4, confirming the pathological nature of the variants. Further analysis of fibroblasts allowed to establish that increased mitochondrial mass, mitochondrial fragmentation, and augmented autophagy are associated with FBXL4 deficiency in cells, but are probably secondary to a primary metabolic defect affecting oxidative phosphorylation.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Uridine Prevents Negative Effects of OXPHOS Xenobiotics on Dopaminergic Neuronal Differentiation

  • Iglesias, Eldris
  • Bayona-Bafaluy, M. Pilar
  • Pesini, Alba
  • Garrido-Pérez, Nuria
  • Meade, Patricia
  • Gaudó, Paula
  • Jiménez-Salvador, Irene
  • Montoya, Julio
  • Ruiz-Pesini, Eduardo
Neuronal differentiation appears to be dependent on oxidative phosphorylation capacity. Several drugs inhibit oxidative phosphorylation and might be detrimental for neuronal differentiation. Some pregnant women take these medications during their first weeks of gestation when fetal nervous system is being developed. These treatments might have later negative consequences on the offspring’s health. To analyze a potential negative effect of three widely used medications, we studied in vitro dopaminergic neuronal differentiation of cells exposed to pharmacologic concentrations of azidothymidine for acquired immune deficiency syndrome; linezolid for multidrug-resistant tuberculosis; and atovaquone for malaria. We also analyzed the dopaminergic neuronal differentiation in brains of fetuses from pregnant mice exposed to linezolid. The drugs reduced the in vitro oxidative phosphorylation capacity and dopaminergic neuronal differentiation. This differentiation process does not appear to be affected in the prenatally exposed fetus brain. Nevertheless, the global DNA methylation in fetal brain was significantly altered, perhaps linking an early exposure to a negative effect in older life. Uridine was able to prevent the negative effects on in vitro dopaminergic neuronal differentiation and on in vivo global DNA methylation. Uridine could be used as a protective agent against oxidative phosphorylation-inhibiting pharmaceuticals provided during pregnancy when dopaminergic neuronal differentiation is taking place.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Oxidative phosphorylation inducers fight pathological angiogenesis

  • Bayona-Bafaluy, M.P.
  • Esteban, O.
  • Ascaso, J.
  • Montoya, J.
  • Ruiz-Pesini, E.
Pathological mutations in subunits of the oxidative phosphorylation (OXPHOS) system, or inhibitors of this biochemical pathway, increase the production of vascular endothelial growth factor (VEGF) and pathological angiogenesis. In many angiogenesis-related diseases, such as retinal, rheumatoid diseases, or cancer, OXPHOS dysfunction can be found. Thus, enhancing OXPHOS might be a promising therapeutic approach for pathologic angiogenesis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Defining the Substrate Spectrum of the TIM22 Complex Identifies Pyruvate Carrier Subunits as Unconventional Cargos

  • Gomkale, R.
  • Cruz-Zaragoza, L.D.
  • Suppanz, I.
  • Guiard, B.
  • Montoya, J.
  • Callegari, S.
  • Pacheu-Grau, D.
  • Warscheid, B.
  • Rehling, P.
In mitochondria, the carrier translocase (TIM22 complex) facilitates membrane insertion of multi-spanning proteins with internal targeting signals into the inner membrane [1–3]. Tom70, a subunit of TOM complex, represents the major receptor for these precursors [2, 4–6]. After transport across the outer membrane, the hydrophobic carriers engage with the small TIM protein complex composed of Tim9 and Tim10 for transport across the intermembrane space (IMS) toward the TIM22 complex [7–12]. Tim22 represents the pore-forming core unit of the complex [13, 14]. Only a small subset of TIM22 cargo molecules, containing four or six transmembrane spans, have been experimentally defined. Here, we used a tim22 temperature-conditional mutant to define the TIM22 substrate spectrum. Along with carrier-like cargo proteins, we identified subunits of the mitochondrial pyruvate carrier (MPC) as unconventional TIM22 cargos. MPC proteins represent substrates with atypical topology for this transport pathway. In agreement with this, a patient affected in TIM22 function displays reduced MPC levels. Our findings broaden the repertoire of carrier pathway substrates and challenge current concepts of TIM22-mediated transport processes.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Reseña (Review)

Oxidative phosphorylation dysfunction modifies the cell secretome

  • Garrido-Pérez, Nuria
  • Vela-Sebastián, Ana
  • López-Gallardo, Ester
  • Emperador, Sonia
  • Iglesias, Eldris
  • Meade, Patricia
  • Jiménez-Mallebrera, Cecilia
  • Montoya, Julio
  • Bayona-Bafaluy, M. Pilar
  • Ruiz-Pesini, Eduardo
Mitochondrial oxidative phosphorylation disorders are extremely heterogeneous conditions. Their clinical and genetic variability makes the identification of reliable and specific biomarkers very challenging. Until now, only a few studies have focused on the effect of a defective oxidative phosphorylation functioning on the cell’s secretome, although it could be a promising approach for the identification and pre-selection of potential circulating biomarkers for mitochondrial diseases. Here, we review the insights obtained from secretome studies with regard to oxidative phosphorylation dysfunction, and the biomarkers that appear, so far, to be promising to identify mitochondrial diseases. We propose two new biomarkers to be taken into account in future diagnostic trials.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Ketogenic treatment reduces the percentage of a LHON heteroplasmic mutation and increases mtDNA amount of a LHON homoplasmic mutation.

  • Emperador, Sonia
  • López-Gallardo, Ester
  • Hernández-Ainsa, Carmen
  • Habbane, Mouna
  • Montoya, Julio
  • Bayona-Bafaluy, M. Pilar
  • Ruiz-Pesini, Eduardo
Background: The vision loss in Leber hereditary optic neuropathy patients is due to mitochondrial DNA mutations. No treatment has shown a clear-cut benefit on a clinically meaningful end-point. However, clinical evidences suggest two therapeutic approaches: the reduction of the mutation load in heteroplasmic patients or the elevation of mitochondrial DNA amount in homoplasmic patients. Results: Here we show that ketogenic treatment, in cybrid cell lines, reduces the percentage of the m.13094 T > C heteroplasmic mutation and also increases the mitochondrial DNA levels of the m.11778G > A mitochondrial genotype. Conclusions: These results suggest that ketogenic diet could be a therapeutic strategy for Leber hereditary optic neuropathy.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Mitochondrial DNA pathogenic mutations in multiple symmetric lipomatosis

  • López-Gallardo, Ester
  • Cammarata-Scalisi, Francisco
  • Emperador, Sonia
  • Hernández-Ainsa, Carmen
  • Habbane, Mouna
  • Vela-Sebastián, Ana
  • Bayona-Bafaluy, María Pilar
  • Montoya, Julio
  • Ruiz-Pesini, Eduardo
The frequency of dermatological manifestations in diseases due to mitochondrial DNA mutations is not well known, although multiple symmetric lipomatosis has been repeatedly associated to mitochondrial DNA mutations. Here, we present a patient suffering from multiple symmetric lipomatosis and other skin signs. We found a new mitochondrial DNA mutation, m.8357T>C, in the tRNALys-coding gene and, using a cybrid approach, confirmed its pathogenicity. A meta-analysis of the dermatological signs of the patient shows that they are not common in patients with confirmed mitochondrial DNA mutations and suggests that, in these cases, lipomatosis is not related to the oxidative phosphorylation dysfunction, but to an alteration of an additional function associated to particular mitochondrial tRNAs.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Brain pyrimidine nucleotide synthesis and Alzheimer disease

  • Pesini, Alba
  • Iglesias, Eldris
  • Bayona-Bafaluy, M Pilar
  • Garrido-Pérez, Nuria
  • Meade, Patricia
  • Gaudó, Paula
  • Jiménez-Salvador, Irene
  • Andrés-Benito, Pol
  • Montoya, Julio
  • Ferrer, Isidro
  • Pesini, Pedro
  • Ruiz-Pesini, Eduardo
Many patients suffering late-onset Alzheimer disease show a deficit in respiratory complex IV activity. The de novo pyrimidine biosynthesis pathway connects with the mitochondrial respiratory chain upstream from respiratory complex IV. We hypothesized that these patients would have decreased pyrimidine nucleotide levels. Then, different cell processes for which these compounds are essential, such as neuronal membrane generation and maintenance and synapses production, would be compromised. Using a cell model, we show that inhibiting oxidative phosphorylation function reduces neuronal differentiation. Linking these processes to pyrimidine nucleotides, uridine treatment recovers neuronal differentiation. To unmask the importance of these pathways in Alzheimer disease, we firstly confirm the existence of the de novo pyrimidine biosynthesis pathway in adult human brain. Then, we report altered mRNA levels for genes from both de novo pyrimidine biosynthesis and pyrimidine salvage pathways in brain from patients with Alzheimer disease. Thus, uridine supplementation might be used as a therapy for those Alzheimer disease patients with low respiratory complex IV activity.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Development and characterization of cell models harbouring mtDNA deletions for <i>in vitro</i> study of Pearson syndrome

  • Hernández-Ainsa, Carmen
  • López-Gallardo, Ester
  • García-Jiménez, María Concepción
  • Climent-Alcalá, Francisco José
  • Rodríguez-Vigil, Carmen
  • García Fernández de Villalta, Marta
  • Artuch, Rafael
  • Montoya, Julio
  • Ruiz-Pesini, Eduardo
  • Emperador, Sonia
Pearson syndrome is a rare multisystem disease caused by single large-scale mitochondrial DNA deletions (SLSMDs). The syndrome presents early in infancy and is mainly characterised by refractory sideroblastic anaemia. Prognosis is poor and treatment is supportive, thus the development of new models for the study of Pearson syndrome and new therapy strategies is essential. In this work, we report three different cell models carrying an SLMSD: fibroblasts, transmitochondrial cybrids and induced pluripotent stem cells (iPSCs). All studied models exhibited an aberrant mitochondrial ultrastructure and defective oxidative phosphorylation system function, showing a decrease in different parameters, such as mitochondrial ATP, respiratory complex IV activity and quantity or oxygen consumption. Despite this, iPSCs harbouring ‘common deletion’ were able to differentiate into three germ layers. Additionally, cybrid clones only showed mitochondrial dysfunction when heteroplasmy level reached 70%. Some differences observed among models may depend on their metabolic profile; therefore, we consider that these three models are useful for the in vitro study of Pearson syndrome, as well as for testing new specific therapies. This article has an associated First Person interview with the first author of the paper.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Síndrome de Leigh de inicio adulto, con epilepsia mioclónica progresiva, asociado a la mutación m.14487T>C: reporte de caso

  • Segura-Chávez, Darwin
  • Torres-Ramírez, Luis
  • Emperador-Ortiz, Sonia
  • Vélez-Rojas, Miriam
  • Flores-Mendoza, Martha
  • Cosentino-Esquerre, Carlos
  • Ruiz-Pesini, Eduardo
  • Montoya-Villarroya, Julio
El síndrome de Leigh o encefalomielopatía necrotizante subaguda es una enfermedad neurodegenerativa progresiva, genética y clínicamente heterogénea que se asocia por lo general con alteración del metabolismo mitocondrial a nivel de la fosforilación oxidativa. Se presenta generalmente en el periodo neonatal, pero también en la edad adulta, en la que suele expresarse con una combinación de diversas manifestaciones entre ellas parkinsonismo, alteraciones del movimiento, alteraciones neuropsiquiátricas y otras. Caso clínico Paciente masculino de 34 años de edad, que inició sus síntomas a los 18 años, algunos meses después de que su madre falleciera con síntomas parecidos, pero sin diagnóstico definido. El paciente presentó mioclonías progresivas en miembro superior derecho, espasmos palpebrales bilaterales y cervicales, asociándose posteriormente, mioclonia facial desencadenado por el habla y distonía en miembro inferior derecho que le impedía la deambulación. La resonancia magnética de encéfalo mostró la presencia de lesiones simétricas bilaterales en núcleos basales, lesiones corticales y periacueductales. El estudio genético detectó la mutación m.14487T>C en el gen ND6 del complejo 1 del sistema de fosforilación oxidativa mitocondrial en los leucocitos y células de mucosa bucal. El estudio se extendió a la abuela y dos tías maternas, asintomáticas en ese momento, quienes portaban la misma mutación. Conclusión El caso corresponde a un paciente adulto, con síndrome de Leigh, portador de la mutación m.14487T>C, la cual parece estar relacionada con un fenotipo predominantemente mioclónico progresivo, de origen cortical.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Prenatal exposure to oxidative phosphorylation xenobiotics and late-onset Parkinson disease

  • Iglesias, E.
  • Pesini, A.
  • Garrido-Pérez, N.
  • Meade, P.
  • Bayona-Bafaluy, M.P.
  • Montoya, J.
  • Ruiz-Pesini, E.
Late-onset Parkinson disease is a multifactorial and multietiological disorder, age being one of the factors implicated. Genetic and/or environmental factors, such as pesticides, can also be involved. Up to 80% of dopaminergic neurons of the substantia nigra are lost before motor features of the disorder begin to appear. In humans, these neurons are only formed a few weeks after fertilization. Therefore, prenatal exposure to pesticides or industrial chemicals during crucial steps of brain development might also alter their proliferation and differentiation. Oxidative phosphorylation is one of the metabolic pathways sensitive to environmental toxicants and it is crucial for neuronal differentiation. Many inhibitors of this biochemical pathway, frequently found as persistent organic pollutants, affect dopaminergic neurogenesis, promote the degeneration of these neurons and increase the risk of suffering late-onset Parkinson disease. Here, we discuss how an early, prenatal, exposure to these oxidative phosphorylation xenobiotics might trigger a late-onset, old age, Parkinson disease.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Down syndrome is an oxidative phosphorylation disorder

  • Bayona-Bafaluy, M.P.
  • Garrido-Pérez, N.
  • Meade, P.
  • Iglesias, E.
  • Jiménez-Salvador, I.
  • Montoya, J.
  • Martínez-Cué, C.
  • Ruiz-Pesini, E.
Down syndrome is the most common genomic disorder of intellectual disability and is caused by trisomy of chromosome 21. Several genes in this chromosome repress mitochondrial biogenesis. The goal of this study was to evaluate whether early overexpression of these genes may cause a prenatal impairment of oxidative phosphorylation negatively affecting neurogenesis. Reduction in the mitochondrial energy production and a lower mitochondrial function have been reported in diverse tissues or cell types, and also at any age, including early fetuses, suggesting that a defect in oxidative phosphorylation is an early and general event in Down syndrome individuals. Moreover, many of the medical conditions associated with Down syndrome are also frequently found in patients with oxidative phosphorylation disease. Several drugs that enhance mitochondrial biogenesis are nowadays available and some of them have been already tested in mouse models of Down syndrome restoring neurogenesis and cognitive defects. Because neurogenesis relies on a correct mitochondrial function and critical periods of brain development occur mainly in the prenatal and early neonatal stages, therapeutic approaches intended to improve oxidative phosphorylation should be provided in these periods.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Leigh Syndrome in a Pedigree Harboring the m.1555A>G Mutation in the Mitochondrial 12S rRNA

  • Habbane, M.
  • Llobet, L.
  • Bayona-Bafaluy, M.P.
  • Bárcena, J.E.
  • Ceberio, L.
  • Gómez-Díaz, C.
  • Gort, L.
  • Artuch, R.
  • Montoya, J.
  • Ruiz-Pesini, E.
BACKGROUND: Leigh syndrome (LS) is a serious genetic disease that can be caused by mutations in dozens of different genes. METHODS: Clinical study of a deafness pedigree in which some members developed LS. Cellular, biochemical and molecular genetic analyses of patients'' tissues and cybrid cell lines were performed. RESULTS: mitochondrial DNA (mtDNA) m.1555A>G/MT-RNR1 and m.9541T>C/MT-CO3 mutations were found. The first one is a well-known pathologic mutation. However, the second one does not appear to contribute to the high hearing loss penetrance and LS phenotype observed in this family. CONCLUSION: The m.1555A>G pathological mutation, accompanied with an unknown nuclear DNA (nDNA) factor, could be the cause of the phenotypic manifestations in this pedigree.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Infectious stress triggers a POLG-related mitochondrial disease

  • Gaudo, Paula
  • Emperador, Sonia
  • Garrido-Perez, Nuria
  • Ruiz-Pesini, Eduardo
  • Yubero, Delia
  • Garcia-Cazorla, Angels
  • Artuch, Rafael
  • Montoya, Julio
  • Bayona-Bafaluy, María Pilar
A 3-year-old girl presented with severe epilepsy in the context of Borrelia infection. After ceftriaxone/lidocaine administration, she showed secondarily generalized focal crises that led to neurological and motor sequelae. Genetic studies identified in the patient two heterozygous POLG mutations (c.2591A>G; p.Asn864Ser and c.3649G>C; p.Ala1217Pro). Through analysis of POLG activity in cultured fibroblasts, we confirmed that the mutations altered the mtDNA turnover. Moreover, patient fibroblasts were more sensitive than controls in the presence of a mitochondrial replication-affecting drug, the antiretroviral azidothymidine. To test if ceftriaxone treatment could worsen the deleterious effect of the patient mutations, toxicity assays were performed. Cell toxicity, without direct effect on mitochondrial respiratory function, was detected at different antibiotic concentrations. The clinical outcome, together with the different in vitro sensitivity to ceftriaxone among patient and control cells, suggested that the mitochondrial disease symptoms were hastened by the infection and were possibly worsened by the pharmacological treatment. This study underscores the benefit of early genetic diagnosis of the patients with mitochondrial diseases, since they may be a target group of patients especially vulnerable to environmental factors.